Literature DB >> 14666002

Survival after myocardial revascularization for ischemic cardiomyopathy: a prospective ten-year follow-up study.

Pallav J Shah1, David L Hare, Jai S Raman, Ian Gordon, Robert K Chan, John D Horowitz, Alex Rosalion, Brian F Buxton.   

Abstract

OBJECTIVE: The aim was to prospectively analyze all-cause mortality, predictors of survival, and late functional results after myocardial revascularization for ischemic cardiomyopathy over a 10-year follow-up.
METHODS: We prospectively studied 57 patients with stable coronary artery disease and poor left ventricular ejection function (<35%), enrolled between 1989 and 1994. Stress thallium was analyzed in 37 patients to identify reversible ischemia. To avoid patients with a stunned myocardium, we excluded those with unstable angina or myocardial infarction within the previous 4 weeks. Mean age of the patients was 67 +/- 8 years, and 93% of patients were men. Mean left ventricular ejection fraction was 0.28 +/- 0.04, 50% were in Canadian Cardiovascular Society angina class III-IV, and 65% were in New York Heart Association functional class III-IV.
RESULTS: Operative mortality was 1.7% (1/57). The mean left ventricular ejection fraction (0.30) at 15 months postoperatively did not change from before operation (0.28, P =.09). There were 8 deaths at 1 year and 42 deaths over the course of the study, producing a survival of 82.5% at 1 year, 55.7% at 5 years, and 23.9% at 10 years (95% confidence interval: 14.6%-39.1%). Symptom-free survival was 77.2% at 1 year and 20.3% at 10 years. The leading cause of death was heart failure in 29% (12/42). Multivariate analysis showed that large reversible defects on stress thallium were associated with improved left ventricular ejection fraction at 1 year (P =.01) but only male sex was associated with improved long-term survival (P =.036).
CONCLUSIONS: Myocardial revascularization for ischemic cardiomyopathy is associated with good functional relief from the symptoms of angina initially and, to a lesser extent, heart failure. Revascularization may have the advantage of preserving the remaining left ventricular function. However, the long-term mortality remains high.

Entities:  

Mesh:

Year:  2003        PMID: 14666002     DOI: 10.1016/s0022-5223(03)00809-2

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

1.  Surgical ventricular restoration: the RESTORE Group experience.

Authors:  Constantine L Athanasuleas; Gerald D Buckberg; Alfred W H Stanley; William Siler; Vincent Dor; Marisa DiDonato; Lorenzo Menicanti; Sergio Almeida de Oliveira; Friedhelm Beyersdorf; Irving L Kron; Hisayoshi Suma; Nicholas T Kouchoukos; Wistar Moore; Patrick M McCarthy; Mehmet C Oz; Francis Fontan; Meredith L Scott; Kevin A Accola
Journal:  Heart Fail Rev       Date:  2004-10       Impact factor: 4.214

2.  Revascularization among patients with severe left ventricular dysfunction: a meta-analysis of observational studies.

Authors:  Vijayalakshmi Kunadian; Azfar Zaman; Weiliang Qiu
Journal:  Eur J Heart Fail       Date:  2011-04-08       Impact factor: 15.534

3.  Role of surgical ventricular restoration post surgical treatment of heart failure (STICH) trial.

Authors:  Anjith Prakash Rajakumar; Mithun Sundararaaja Ravikumar; Vijayanand Palanisamy; Karthik Raman; Anbarasu Mohanraj; Jacob Jamesraj; Valikapthalil Mathew Kurian; Mullasari Ajit; Rajan Sethuratnam
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2018-11-05

4.  Long-term survival and functional recovery after isolated coronary artery bypass grafting in patients with severe left ventricular dysfunction.

Authors:  Toshihiro Fukui; Toshihiko Shibata; Yasuyuki Sasaki; Hidekazu Hirai; Manabu Motoki; Yosuke Takahashi; Atsushi Nakahira; Shigefumi Suehiro
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-10

5.  Preoperative ejection fraction as a predictor of survival after coronary artery bypass grafting: comparison with a matched general population.

Authors:  Mohamed A Soliman Hamad; Albert H M van Straten; Jacques P A M Schönberger; Joost F ter Woorst; Andre M de Wolf; Elisabeth J Martens; André A J van Zundert
Journal:  J Cardiothorac Surg       Date:  2010-04-23       Impact factor: 1.637

6.  Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance.

Authors:  Atul R Chugh; Garth M Beache; John H Loughran; Nathan Mewton; Julius B Elmore; Jan Kajstura; Patroklos Pappas; Antone Tatooles; Marcus F Stoddard; Joao A C Lima; Mark S Slaughter; Piero Anversa; Roberto Bolli
Journal:  Circulation       Date:  2012-09-11       Impact factor: 29.690

Review 7.  Role of cardiac surgery in the post-myocardial infarction patient with heart failure.

Authors:  Marzia Leacche; Jorge M Balaguer; John G Byrne
Journal:  Curr Heart Fail Rep       Date:  2008-12

8.  Revascularization surgery as a treatment concept for heart failure.

Authors:  J Ennker; S Bauer; I C Ennker
Journal:  HSR Proc Intensive Care Cardiovasc Anesth       Date:  2013
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.